Schrödinger, Inc.

SDGR

US80810D1037

Software

Market Closed - Nasdaq Other stock markets 16:00:00 2024-05-17 EDT			5-day change	1st Jan Change
22.76 ^USD	-0.61%		+0.13%	-36.42%

05-13	Ajax Therapeutics, Inc. announced that it has received $95 million in funding from a group of investors	CI
05-07	Ansys Partners With Schrodinger to Accelerate Materials Development	MT

Schrödinger, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024

May 01, 2024 at 04:04 pm

Schrödinger, Inc. reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported sales was USD 3.18 million compared to USD 32.57 million a year ago. Revenue was USD 36.6 million compared to USD 64.78 million a year ago.

Net loss was USD 54.72 million compared to net income of USD 129.14 million a year ago. Basic loss per share from continuing operations was USD 0.76 compared to basic earnings per share from continuing operations of USD 1.81 a year ago. Diluted loss per share from continuing operations was USD 0.76 compared to diluted earnings per share from continuing operations of USD 1.75 a year ago.

Latest news about Schrödinger, Inc.

Ajax Therapeutics, Inc. announced that it has received $95 million in funding from a group of investors	05-12	CI
Ansys Partners With Schrodinger to Accelerate Materials Development	05-07	MT
Earnings Flash (SDGR) SCHRODINGER Reports Q1 Revenue $36.6M, vs. Street Est of $42M	05-01	MT
Transcript : Schrödinger, Inc., Q1 2024 Earnings Call, May 01, 2024	05-01
Schrödinger, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-01	CI
Schrödinger, Inc. Provides Earnings Guidance for the Second Quarter of 2024 and Fiscal Year Ending December 31, 2024	05-01	CI
Citigroup Cuts Schrodinger Price Target to $39 From $47, Maintains Buy Rating	03-01	MT
Goldman Sachs Cuts Schrodinger's Price Target to $26 From $29, Keeps Neutral Rating	03-01	MT
Piper Sandler Cuts Price Target on Schrodinger to $50 From $60, Maintains Overweight Rating	02-29	MT
Schrodinger's Q4 Adjusted Net Loss Narrows, Revenue Increases; Shares Down Pre-Bell	02-29	MT
Transcript : Schrödinger, Inc., Q4 2023 Earnings Call, Feb 28, 2024	02-28
Earnings Flash (SDGR) SCHRODINGER Posts Q4 Revenue $74.1M, vs. Street Est of $79.1M	02-28	MT
Schrödinger, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	02-28	CI
TD Cowen Starts Schrodinger With Outperform Rating, $42 Price Target	01-26	MT
Sector Update: Health Care Stocks Ease Thursday Afternoon	12-14	MT
Schrodinger Shares Rise as SGR-1505 Seen Well-tolerated in Early Trial; Three New Gene Mutation Programs Added	12-14	MT
Transcript : Schrödinger, Inc. - Special Call	12-14
Schrodinger Says New Data Show 'Multiple Favorable Attributes' of Potential Leukemia Treatments	12-11	MT
KeyBanc Initiates Schrodinger at Overweight With $38 Price Target, Cites 'Healthy Recurring Revenue Growth' in Software & Services, 'Attractive Valuation'	12-05	MT
Morgan Stanley Trims Price Target on Schrodinger to $51 From $52, Maintains Equal-Weight Rating	11-13	MT
Transcript : Schrödinger, Inc., Q3 2023 Earnings Call, Nov 01, 2023	11-01
Schrodinger Q3 Non-GAAP Loss Widens, Revenue Increases	11-01	MT
Earnings Flash (SDGR) SCHRODINGER Posts Q3 Revenue $42.6M, vs. Street Est of $37.9M	11-01	MT
Schrödinger, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-01	CI
BofA Securities Lowers Price Target on Schrodinger to $39 From $48, Maintains Neutral Rating	23-10-20	MT

Chart Schrödinger, Inc.

Duration

Period

More charts

Company Profile

Schrodinger, Inc. operates a physics-based computational platform that enables the discovery of molecules for drug development and materials applications. The software platform is used by biopharmaceutical and industrial companies, academic institutions, and government laboratories around the world. The Company operates through two segments: Software and Drug Discovery. The Software segment is focused on selling its software to transform drug discovery across the life sciences industry, as well as to customers in materials science industries. The Drug Discovery segment is focused on building a diverse portfolio of preclinical and clinical programs, internally and through collaborations, that have advanced to various stages of discovery and development. The Company's pipeline of drug discovery programs includes SGR-1505 (MALT1 Inhibitor), SGR-2921 (CDC7 Inhibitor), SGR-3515 (WEE1 Inhibitor). Its software was used by researchers around the world at more than 1,760 academic institutions.

Sector

Software

Calendar

2024-06-18 - Annual General Meeting

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Schrödinger, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

22.76 USD

Average target price

36.5 USD

Spread / Average Target

+60.37%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Software

	1st Jan change	Capi.
SCHRÖDINGER, INC.	-36.42%	1.65B
MICROSOFT CORPORATION	+11.75%	3,123B
SYNOPSYS INC.	+10.06%	86.45B
CADENCE DESIGN SYSTEMS, INC.	+6.04%	78.6B
DASSAULT SYSTÈMES SE	-14.66%	53.98B
PALANTIR TECHNOLOGIES INC.	+26.73%	48.46B
ATLASSIAN CORPORATION	-24.44%	46.78B
THE TRADE DESK, INC.	+31.74%	46.36B
SEA LIMITED	+82.12%	42.36B
TAKE-TWO INTERACTIVE SOFTWARE, INC.	-8.15%	25.22B

Other Software